LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Nanogen and Transgenomic in Distribution Agreement

By HospiMedica staff writers
Posted on 30 Jan 2004
A distribution agreement has been announced by Nanogen, Inc. (San Diego, CA, USA) and Transgenomic, Inc. (Omaha, NE, USA) that will allow Transgenomic to distribute Nanogen's NanoChip Molecular Biology Workstation in selected western European countries.

The NanoChip Workstation is an automated, open-architecture instrument that facilitates routine detection of known genetic variations, such as single nucleotide polymorphisms (SNPs) and short tandem repeats (STRs), complementing the Transgenomic Wave system's ability to scan for unknown genetic variations. The Wave technology has proven highly effective in detecting low-abundance genetic variation, such as somatic mutations that may arise during the course of cancer progression or in the development of drug resistance. The Wave systems have broad applicability to genetic research and molecular diagnostics. More than 1,000 systems have been installed around the world.

"This agreement is part of a strategy of providing total complementary solutions for the genetic research and clinical laboratory markets in Europe,” noted Collin D'Silva, CEO of Transgenomic. "We foresee significant synergy from the addition of the Nanogen platform to our well-established European marketing efforts.”




Related Links:
Nanogen
Transgenomic

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control

Latest Industry News

New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
30 Jan 2004  |   Industry

Fujirebio Expands Access to Automated Blood-Based Neurology Testing in Canada
30 Jan 2004  |   Industry

Natera ctDNA Test to Support Response Monitoring in Solid Tumor Trial
30 Jan 2004  |   Industry